Kind-Philipp-Foundation for Research in Pediatric Oncology
XXXIII. Annual Meeting | June 3-6, 2020

Transport

Bus transfer from HH-Dammtor, exit CCH (Congress Centrum Hamburg), on 03.06.2019, 15:30 h (Bus with sign „Undeloh/Wilsede“).
The bus travels back from Undeloh to HH-Dammtor on Saturday, 06.06.19, at 9:00 h.

Download Scientific Program
Download Abstract Book

WEDNESDAY, June 3, 2020

16:00 – 17:30 h

16:00 – 17:30 h

Welcome and registration

Welcome and registration

17:30 – 17:45 h

17:30 – 17:45 h

Opening of the meeting – Rolf Marschalak

Opening of the meeting

17:45 – 18:30 h

17:45 – 18:30 h

(1) Opening Lecture

(1) Opening Lecture

Chair: Jan-Henning Klusmann

Prof. Dr. Thomas Mercher
Ontogeny-dependent susceptibility to fusion oncogenes controls pediatric myeloid leukemia

Institut Gustave Roussy; Villejuif

18:30 – 19:45 h

18:30 – 19:45 h

(2) Omics studies

(2) Omics studies

Chair: Thomas Sternsdorf

2.a Mutational and transcriptomic landscapes in hematopoietic cells of Fanconi anemia patients.
Mittapalli, VR; Freiburg

2.b Mapping the single cell transcriptome reveals the cellular composition of ATRT subgroups
Buellesbach, A; Heidelberg

2.c Giant cell glioblastoma does not represent a distinct entity but stratifies into different genetically defined entities
Wiedey, A; Bonn

2.d WNT Medulloblastoma: More than just β-Catenin Mutations – Rare Genetic Features in the Focus
Goschzik, T; Bonn

2.e Epigenetics profiling for minimal residual disease in paediatric acute myeloid leukaemia
Al Ameri, M; London

19:45 h

19:45 h

Dinner

Dinner

Why meeting in Wilsede makes a difference

Wilsede is a very special place: scientists from all over Europe arrive in Undeloh (near Hamburg) and take horse-drawn carriages that transport them to Wilsede, passing a unique landscape (Lueneburg Heath) along the way. Wilsede itself also offers a distinctive scenery: old houses with thatched roofs, a restaurant and the spacious Wilsede barn that is the congress site. Participants can enjoy three days of cancer science surrounded by a charming atmosphere, with nice accomodation and “local cuisine”, including the famous grilled German Black Heath mutton (Heidschnucke).

For more than 30 years, in the early days of June, cancer researchers meet here to share their findings. Wilsede is an especially excellent opportunity for young researchers in the field of pediatric cancer. In a climate of trust and confidence, their latest research can be discussed with experienced colleagues. Everyone who has ever had the chance to attend one of these meetings wants to return. This is the spirit of our annual Wilsede meetings. We warmly invite you to become a part of it.

THURSDAY, June 4, 2020

09:00 – 10:45 h

09:00 – 10:45 h

(3) Molecular mechanisms of disease I

(3) Molecular mechanisms of disease I

Chair: Owen Williams

3.a Splicing factors of the SF3b complex PHF5A and SF3B1 regulate the DNA damage response in ALL
Moorthy, S; Newcastle upon Tyne

3.b Inactivation of Nsd1 impairs terminal erythroid maturation and induces erythroleukemia
Tauchmann, S; Basel

3.c TRIM28 haploinsufficiency predisposes to Wilms tumor
Metzler, M; Erlangen

3.d CRISPR-mediated genome editing of t(4;11) in human prenatal and perinatal hematopoietic stem/progenitor cells
Torres-Ruiz, R; Barcelona

3.e Therapeutic application of the tumour suppressive miR-193b in acute myeloid leukaemia
Issa, H; Halle

3.f Genome-wide CRISPR screen in patient derived cells reveals the mechanism of ALL chemoresistance
Szoltysek, K; Newcastle upon Tyne

3.g GCRISPRi screen to identify functional long noncoding RNAs in pediatric acute myeloid leukemia
Ng, M; Halle

10:45 – 11:00 h

10:45 – 11:00 h

Coffee break

Coffee break

11:00 – 12:45 h

11:00 – 12:45 h

(4) Drugs I

(4) Drugs I

Chair: Torsten Pietsch

4.a Tumour Necrosis Factor receptor (TNFR)-signalling dependent killing in T- cell acute lymphoblastic leukaemia (T-ALL)
Krippner-Heidenreich, A; Utrecht

4.b iPSC Model of Stepwise Leukemia Development in Congenital Neutropenia Reveals BAALC as a Key Mediator of Leukemogenesis
Dannenmann, B; Tübingen

4.c Targeting c-MYB in Acute Leukaemia through Drug Repositioning
Clesham KJ; London

4.d Functional analysis of class I HDAC inhibition in group 3 medulloblastoma to identify synergistic drug combinations
Vollmer, J; Heidelberg

4.e Screening assay to identify potential Taspase1 inhibitors
Luciano, V; Frankfurt

4.f Analyzing the therapeutic efficacy of navitoclax and MCL-1 inhibitors in juvenile myelomonyctic leukemia
Wu, Y; Freiburg

4.g Establishment of new therapeutic options for the treatment of Myeloid Leukemia in Down syndrome (ML-DS)
Samulowski, D; Halle

12:45 – 14:15 h

12:45 – 14:15 h

Lunch (Wilsede, Heidemuseum)

Lunch (Wilsede, Heidemuseum)

14:15 – 15:45 h

14:15 – 15:45 h

(5) Diagnostics and Biomarkers

(5) Diagnostics and Biomarkers

Chair: Roland Kappler

5.a Masked hypodiploidy against uniparental disomies in hyperdiploid ALL: Observations from the diagnostics perspective
Schieck, M; Hannover

5.b Large amplicon droplet digital PCR for DNA-based monitoring of pediatric chronic myeloid leukemia (CML)
Krumbholz, M; Erlangen

5.c Stratification and prognosis of IGH-DUX4 positive acute lymphoblastic leukemia in children
Müller, J; Kiel

5.d Multiplex droplet digital PCR-based targeted enrichment NGS for identification of tumor markers in Ewing sarcoma (EwS)
Eiblwieser, J; Erlangen

5.e Machine learning algorithms for the automated classification of pediatric anemia
Zierk, J; Erlangen

5.f Identification of the genetic mechanisms linked to the occurrence of H3.3K27M mutation in pediatric diffuse intrinsic pontine gliomas
Kubiak, K; Göttingen

15:45 – 16:15 h

15:45 – 16:15 h

Coffee break

Coffee break

16:15 – 17:45 h

16:15 – 17:45 h

(6) Molecular mechanisms of disease II

(6) Molecular mechanisms of disease II

Chair: Deepali Pal

6.a Deciphering the interactive network of the DLK1-DIO3 locus in hematopoiesis and pediatric acute megakaryoblastic leukemia
Verboon LJ; Halle

6.b Identification of GATA1s interaction partners in Down syndrome-associated myeloid leukemia
Bräuer-Hartmann, D; Halle

6.c Isolation and characterization of tumor-derived exosomes from a patient-derived xenograft mouse model of acute leukemia
Bartholomé, R; München

6.d Interrogating the role of chromatin regulator BRD4 in the DNA damage response in medulloblastoma
Vu-Han, T-L; Hamburg

6.e Analyzing the effects of oncogenic SHP2 on apoptosis signaling during malignant transformation
Koleci, N; Freiburg

6.f Cooperativity between miR-125b and Gata1s in the pathogenesis of Down syndrome-associated myeloid leukemia
Alejo-Valle, O; Halle

18:15 – 19:00 h

18:15 – 19:00 h

(7) Invited Lecture:

(7) Invited Lecture:

Chair: Karl Welte

Senior-Prof. em. Dr. Meinolf Suttorp
Do you know a chimera?

Pediatric Hematology and Oncology, Medical Faculty, Technical University Dresden; Dresden

19:00 h

16:50 – 17:15 h

Barbecue

Barbecue

Starting later

Starting later

Evening with the famous Mac-Guitar

Evening with the famous Mac-Guitar

Why meeting in Wilsede makes a difference

Wilsede is a very special place: scientists from all over Europe arrive in Undeloh (near Hamburg) and take horse-drawn carriages that transport them to Wilsede, passing a unique landscape (Lueneburg Heath) along the way. Wilsede itself also offers a distinctive scenery: old houses with thatched roofs, a restaurant and the spacious Wilsede barn that is the congress site. Participants can enjoy three days of cancer science surrounded by a charming atmosphere, with nice accomodation and “local cuisine”, including the famous grilled German Black Heath mutton (Heidschnucke).

For more than 30 years, in the early days of June, cancer researchers meet here to share their findings. Wilsede is an especially excellent opportunity for young researchers in the field of pediatric cancer. In a climate of trust and confidence, their latest research can be discussed with experienced colleagues. Everyone who has ever had the chance to attend one of these meetings wants to return. This is the spirit of our annual Wilsede meetings. We warmly invite you to become a part of it.

FRIDAY, June 5, 2020

09:00 – 10:45 h

09:00 – 10:45 h

(3) Molecular mechanisms of disease I

(3) Molecular mechanisms of disease I

Chair: Owen Williams

3.a Splicing factors of the SF3b complex PHF5A and SF3B1 regulate the DNA damage response in ALL
Moorthy, S; Newcastle upon Tyne

3.b Inactivation of Nsd1 impairs terminal erythroid maturation and induces erythroleukemia
Tauchmann, S; Basel

3.c TRIM28 haploinsufficiency predisposes to Wilms tumor
Metzler, M; Erlangen

3.d CRISPR-mediated genome editing of t(4;11) in human prenatal and perinatal hematopoietic stem/progenitor cells
Torres-Ruiz, R; Barcelona

3.e Therapeutic application of the tumour suppressive miR-193b in acute myeloid leukaemia
Issa, H; Halle

3.f Genome-wide CRISPR screen in patient derived cells reveals the mechanism of ALL chemoresistance
Szoltysek, K; Newcastle upon Tyne

3.g GCRISPRi screen to identify functional long noncoding RNAs in pediatric acute myeloid leukemia
Ng, M; Halle

10:45 – 11:00 h

10:45 – 11:00 h

Coffee break

Coffee break

11:00 – 12:45 h

11:00 – 12:45 h

(4) Drugs I

(4) Drugs I

Chair: Torsten Pietsch

4.a Tumour Necrosis Factor receptor (TNFR)-signalling dependent killing in T- cell acute lymphoblastic leukaemia (T-ALL)
Krippner-Heidenreich, A; Utrecht

4.b iPSC Model of Stepwise Leukemia Development in Congenital Neutropenia Reveals BAALC as a Key Mediator of Leukemogenesis
Dannenmann, B; Tübingen

4.c Targeting c-MYB in Acute Leukaemia through Drug Repositioning
Clesham KJ; London

4.d Functional analysis of class I HDAC inhibition in group 3 medulloblastoma to identify synergistic drug combinations
Vollmer, J; Heidelberg

4.e Screening assay to identify potential Taspase1 inhibitors
Luciano, V; Frankfurt

4.f Analyzing the therapeutic efficacy of navitoclax and MCL-1 inhibitors in juvenile myelomonyctic leukemia
Wu, Y; Freiburg

4.g Establishment of new therapeutic options for the treatment of Myeloid Leukemia in Down syndrome (ML-DS)
Samulowski, D; Halle

12:45 – 14:15 h

12:45 – 14:15 h

Lunch (Wilsede, Heidemuseum)

Lunch (Wilsede, Heidemuseum)

14:15 – 15:45 h

14:15 – 15:45 h

(5) Diagnostics and Biomarkers

(5) Diagnostics and Biomarkers

Chair: Roland Kappler

5.a Masked hypodiploidy against uniparental disomies in hyperdiploid ALL: Observations from the diagnostics perspective
Schieck, M; Hannover

5.b Large amplicon droplet digital PCR for DNA-based monitoring of pediatric chronic myeloid leukemia (CML)
Krumbholz, M; Erlangen

5.c Stratification and prognosis of IGH-DUX4 positive acute lymphoblastic leukemia in children
Müller, J; Kiel

5.d Multiplex droplet digital PCR-based targeted enrichment NGS for identification of tumor markers in Ewing sarcoma (EwS)
Eiblwieser, J; Erlangen

5.e Machine learning algorithms for the automated classification of pediatric anemia
Zierk, J; Erlangen

5.f Identification of the genetic mechanisms linked to the occurrence of H3.3K27M mutation in pediatric diffuse intrinsic pontine gliomas
Kubiak, K; Göttingen

15:45 – 16:15 h

15:45 – 16:15 h

Coffee break

Coffee break

16:15 – 17:45 h

16:15 – 17:45 h

(6) Molecular mechanisms of disease II

(6) Molecular mechanisms of disease II

Chair: Deepali Pal

6.a Deciphering the interactive network of the DLK1-DIO3 locus in hematopoiesis and pediatric acute megakaryoblastic leukemia
Verboon LJ; Halle

6.b Identification of GATA1s interaction partners in Down syndrome-associated myeloid leukemia
Bräuer-Hartmann, D; Halle

6.c Isolation and characterization of tumor-derived exosomes from a patient-derived xenograft mouse model of acute leukemia
Bartholomé, R; München

6.d Interrogating the role of chromatin regulator BRD4 in the DNA damage response in medulloblastoma
Vu-Han, T-L; Hamburg

6.e Analyzing the effects of oncogenic SHP2 on apoptosis signaling during malignant transformation
Koleci, N; Freiburg

6.f Cooperativity between miR-125b and Gata1s in the pathogenesis of Down syndrome-associated myeloid leukemia
Alejo-Valle, O; Halle

18:15 – 19:00 h

18:15 – 19:00 h

(7) Invited Lecture:

(7) Invited Lecture:

Chair: Karl Welte

Senior-Prof. em. Dr. Meinolf Suttorp
Do you know a chimera?

Pediatric Hematology and Oncology, Medical Faculty, Technical University Dresden; Dresden

19:00 h

16:50 – 17:15 h

Barbecue

Barbecue

Starting later

Starting later

Evening with the famous Mac-Guitar

Evening with the famous Mac-Guitar

Why meeting in Wilsede makes a difference

Wilsede is a very special place: scientists from all over Europe arrive in Undeloh (near Hamburg) and take horse-drawn carriages that transport them to Wilsede, passing a unique landscape (Lueneburg Heath) along the way. Wilsede itself also offers a distinctive scenery: old houses with thatched roofs, a restaurant and the spacious Wilsede barn that is the congress site. Participants can enjoy three days of cancer science surrounded by a charming atmosphere, with nice accomodation and “local cuisine”, including the famous grilled German Black Heath mutton (Heidschnucke).

For more than 30 years, in the early days of June, cancer researchers meet here to share their findings. Wilsede is an especially excellent opportunity for young researchers in the field of pediatric cancer. In a climate of trust and confidence, their latest research can be discussed with experienced colleagues. Everyone who has ever had the chance to attend one of these meetings wants to return. This is the spirit of our annual Wilsede meetings. We warmly invite you to become a part of it.

SATURDAY, June 6, 2020

09:00 – 10:30 h

09:00 – 10:30 h

(8) Immunotherapy

(8) Immunotherapy

Chair:  Olaf Heidenreich

8.a Development of a novel central nervous system (CNS)-targeted CD19-antibody (AB) in acute lymphoblastic leukemia (ALL)
Winterberg, D; Kiel

8.b CD19 and CD22-directed bispecific CAR for B-cell acute lymphoblastic leukemia
Zanetti, SR; Barcelona

8.c Low regulatory T-cells are associated with improved survival of neuroblastoma patients treated with anti-GD2 antibodies
Troschke-Meurer. S; Greifswald

8.d CRISPR/Cas9 Gene-modification Platform of ELANE Mutations in iPSCs and HSPCs of Severe Congenital Neutropenia Patients
Nasri, M; Tübingen

8.e Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies
Heymann, J; Kiel

8.f Blockade of suppressive myeloid cells is effective against neuroblastoma
von Lojewski, L; Tübingen

10:30 – 10:45 h

10:30 – 10:45 h

Coffee break

Coffee break

10:45 – 12:30 h

10:45 – 12:30 h

(9) Molecular mechanisms of disease III

(9) Molecular mechanisms of disease III

Chair: Jasper de Boer

9.a Too little is too much: Leukemogenesis in the Gata2 syndrome
Weiss, JM; Freiburg

9.b Using acute promyelocytic leukemia to study the H3.3 histone chaperone system and its role in pediatric malignancies
Cui, W; Hamburg

9.c Functional characterization of RUNX1 variants in the context of FPDMM
Decker, M; Hannover

9.d FOS and FOSB are linked with CNS-infiltration and inferior prognosis in childhood T-cell acute lymphoblastic leukemia
Spory, L; Kiel

9.e Deciphering role of lncRNAs in pediatric AML
Bhayadia, R; Halle

9.f Genomic characterisation of lineage switched MLL-rearranged leukemias
Tirtakusuma, R; Newcastle upon Tyne

9.g Downstream effect of CSF3R and RUNX1 mutations that underlie leukemic transformations in congenital neutropenia (CN)
Ritter, MU; Tübingen

12:30 – 13:45 h

12:30 – 13:45 h

Lunch (Wilsede, Heidemuseum)

Lunch (Wilsede, Heidemuseum)

13:45 – 15:00 h

13:45 – 15:00 h

(10) Molecular mechanisms of disease IV

(10) Molecular mechanisms of disease IV

Chair: Markus Metzler

10.a Identification of a new splice variant of the human transcription factor ONECUT2
Lein, P; Halle

10.b NAMPT-mediated LMO2 deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis
Morishima, T; Tübingen

10.c GADD45b plays an essential role in the G-CSF triggered granulocytic differentiation of human hematopoietic cells
Mir, P; Tübingen

10.d Tripartite motif-containing 71 (TRIM71) is a major factor of oncogenic activity in human hepatoblastoma
Jiang, T; München

10.e Chromosome structure and mitotic defects are major pathogenic mechanisms in hyperdiploid childhood B-ALL.
Molina, O; Barcelona

15:00 – 15:15 h

15:00 – 15:15 h

Coffee break

Coffee break

15:15 – 16:45 h

15:15 – 16:45 h

(11) Drugs II

(11) Drugs II

Chair: Julia Skokowa

11.a Investigating HDACi and dnTaspase1 for the treatment of (4;11) leukemic cells
Wilhelm, A; Frankfurt

11.b Dasatinib and dexamethasone offer a novel therapeutic strategy for T-cell acute lymphoblastic leukaemia
Yuzhe, S; Newcastle upon Tyne

11.c Drug repositioning in infant leukaemia
Looi-Somoye, R; London

11.d Synthetic lethality of Wnt pathway activation and asparaginase in drug-resistant acute leukemias
Hinze, L; Hannover

11.e A human BM-iPSC-derived oncogenic niche identifies CDH2 as a therapeutic niche target in leukemia
Pal, D; Newcastle upon Tyne

11.f Inhibition of the polycomb repressive complex 1 (PRC1) as a therapeutic option in childhood liver tumors
Bentrop, M; München

16:45 – 17:00 h

16:45 – 17:00 h

Wilsede Award and subsequent closure of the meeting

Wilsede Award and subsequent closure of the meeting

16:50 – 17:15 h

16:50 – 17:15 h

Farewell at the Emhoff

Farewell at the Emhoff

17:15 h

17:15 h

Departure of the coaches to Undeloh

Departure of the coaches to Undeloh

18:00 h

18:00 h

Bus transfer to Hamburg Dammtor railway

Bus transfer to Hamburg Dammtor railway

Many thanks for making this meeting possible:

Many thanks for making this meeting possible: